KR20060135854A - Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온 - Google Patents

Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온 Download PDF

Info

Publication number
KR20060135854A
KR20060135854A KR1020067020431A KR20067020431A KR20060135854A KR 20060135854 A KR20060135854 A KR 20060135854A KR 1020067020431 A KR1020067020431 A KR 1020067020431A KR 20067020431 A KR20067020431 A KR 20067020431A KR 20060135854 A KR20060135854 A KR 20060135854A
Authority
KR
South Korea
Prior art keywords
phenyl
compound
alkyl
disease
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067020431A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 지 맥개리
카렌 챈드로스
진 메릴
요헨 괴를릿처
슈테파니 카일
볼프강 벤들러
빠뜨릭 베르나르델리
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20060135854A publication Critical patent/KR20060135854A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
KR1020067020431A 2004-04-01 2005-03-30 Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온 Ceased KR20060135854A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55841904P 2004-04-01 2004-04-01
US60/558,419 2004-04-01

Publications (1)

Publication Number Publication Date
KR20060135854A true KR20060135854A (ko) 2006-12-29

Family

ID=34972933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067020431A Ceased KR20060135854A (ko) 2004-04-01 2005-03-30 Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온

Country Status (17)

Country Link
US (1) US7576109B2 (https=)
EP (1) EP1735303B1 (https=)
JP (1) JP4813460B2 (https=)
KR (1) KR20060135854A (https=)
CN (1) CN100516065C (https=)
AT (1) ATE507226T1 (https=)
AU (1) AU2005230837A1 (https=)
BR (1) BRPI0509468A (https=)
CA (1) CA2561738A1 (https=)
DE (1) DE602005027677D1 (https=)
IL (1) IL178167A0 (https=)
MA (1) MA28562B1 (https=)
NO (1) NO20064982L (https=)
NZ (1) NZ550857A (https=)
RU (1) RU2375358C2 (https=)
WO (1) WO2005097762A2 (https=)
ZA (1) ZA200607851B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005230838A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as PPAR delta
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
AU2006299092A1 (en) * 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-(1,2,4)-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US20120020931A1 (en) * 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
ES2277842T3 (es) * 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6506781B1 (en) * 1999-09-08 2003-01-14 Smithkline Beecham Corporation Oxazole PPAR antagonist
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
AU2005230838A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as PPAR delta

Also Published As

Publication number Publication date
WO2005097762A2 (en) 2005-10-20
RU2375358C2 (ru) 2009-12-10
CN1938305A (zh) 2007-03-28
CA2561738A1 (en) 2005-10-20
JP2007531763A (ja) 2007-11-08
US20070060626A1 (en) 2007-03-15
MA28562B1 (fr) 2007-04-03
NZ550857A (en) 2009-12-24
IL178167A0 (en) 2006-12-31
RU2006138485A (ru) 2008-05-10
EP1735303A2 (en) 2006-12-27
ZA200607851B (en) 2008-06-25
US7576109B2 (en) 2009-08-18
DE602005027677D1 (de) 2011-06-09
AU2005230837A1 (en) 2005-10-20
JP4813460B2 (ja) 2011-11-09
BRPI0509468A (pt) 2007-09-11
ATE507226T1 (de) 2011-05-15
CN100516065C (zh) 2009-07-22
NO20064982L (no) 2006-10-31
WO2005097762A3 (en) 2005-12-15
EP1735303B1 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
US7872032B2 (en) 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
RU2632900C2 (ru) Гетероциклические амины и их применение
JP2022504949A (ja) アンドロゲン受容体モジュレーター及びその使用方法
KR102155559B1 (ko) 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제
KR20060135854A (ko) Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온
KR20060123124A (ko) 벤즈이미다졸릴 유도체
US20200223837A1 (en) Benzofuran amides and heteroaromatic analogues thereof for use in therapy
AU2019208634B2 (en) Dihydroindolizinone derivative
KR20070021171A (ko) Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온
MXPA06010935A (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
MXPA06011064A (es) 1,3,4-oxadiazol-2-onas como moduladores de ppardelta y su uso
JP7553030B2 (ja) ジヒドロインドリジノン誘導体を用いたインスリン産生細胞の作製法
BR112019007901B1 (pt) Pirido[3,4-b]indóis substituídos, processo para sua preparação, composição farmacêutica compreendendo o mesmo e seu uso

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091201

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110711

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110929

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110711

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I